Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stock Report

Market Cap: US$2.2b

Deciphera Pharmaceuticals Future Growth

Future criteria checks 2/6

Deciphera Pharmaceuticals is forecast to grow earnings and revenue by 50.6% and 23.6% per annum respectively. EPS is expected to grow by 52.1% per annum. Return on equity is forecast to be -50.1% in 3 years.

Key information

50.6%

Earnings growth rate

52.1%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate23.6%
Future return on equity-50.1%
Analyst coverage

Good

Last updated11 Jun 2024

Recent future growth updates

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGS:DCPH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026377-72-49-1137
12/31/2025265-157-145-1528
12/31/2024204-186-176-1545
3/31/2024175-190-152-152N/A
12/31/2023163-195-147-147N/A
9/30/2023151-194-154-153N/A
6/30/2023144-187-145-144N/A
3/31/2023138-182-152-151N/A
12/31/2022134-179-154-153N/A
9/30/2022122-221-185-185N/A
6/30/2022109-258-223-218N/A
3/31/2022100-286-230-224N/A
12/31/202196-300-247-241N/A
9/30/202191-274-230-223N/A
6/30/202184-258-221-218N/A
3/31/202167-255-232-227N/A
12/31/202042-266-245-240N/A
9/30/202023-271-253-246N/A
6/30/20207-263-229-220N/A
3/31/202025-218-202-197N/A
12/31/201925-192-154-149N/A
9/30/201925-157-124-120N/A
6/30/201925-126-123-122N/A
3/31/2019N/A-126-104-103N/A
12/31/2018N/A-100-88-87N/A
9/30/2018N/A-87-74-73N/A
6/30/2018N/A-75-58-57N/A
3/31/2018N/A-64-47-46N/A
12/31/2017N/A-50N/A-37N/A
9/30/2017N/A-39N/A-31N/A
6/30/2017N/A-33N/A-28N/A
3/31/2017N/A-28N/A-25N/A
12/31/2016N/A-26N/A-23N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DCPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DCPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DCPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DCPH's revenue (23.6% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: DCPH's revenue (23.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DCPH is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/11 21:03
End of Day Share Price 2024/06/11 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Deciphera Pharmaceuticals, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.